Acknowledgements
S., Sarcomas
SARCOMAS
The authors would like to thank the Spanish group for Research on Sarcomas (GEIS) for supporting the study and Bayer for providing drug supply. The authors would like to thank Patricio Ledesma for Data Management. David S. Moura is a recipient of a Sara Borrell postdoctoral fellowship funded by the National Institute of Health Carlos III (ISCIII) (CD20/00155). The authors would also like to thank SELNET project. SELNET has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement Nº. 825806. Authors would like to give a special thanks to all the patients that participated in the study and their relatives.